Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next [Yahoo! Finance]
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
and esophageal cancers, after an interim analysis found no overall survival benefit versus nivolumab plus chemotherapy, while confirming a broadly similar safety profile. In response, Arcus is reallocating R&D toward its HIF-2a inhibitor casdatifan and early-stage immunology and inflammation programs, signaling a major reshaping of its development pipeline around kidney cancer and oral small-molecule therapies. We'll now examine how Arcus's decision to halt STAR-221 and concentrate resources on casdatifan could reshape its longer-term investment narrative. We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year . See the full list for free. To own Arcus Biosciences, you have to believe that its refocused pipeline in kidney cancer and oral immunology drugs can eventually justify ongoing losses and R&D spend. The STAR-221 setback increases near term uncertainty around domvanalimab, but the main short term catalyst now sits with casdatifan clinical
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RCUS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZeMarketBeat
- Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Arcus Biosciences (NYSE:RCUS) was given a new $30.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Arcus Biosciences (NYSE:RCUS) had its price target raised by analysts at HC Wainwright from $28.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
RCUS
Earnings
- 8/6/25 - Beat
RCUS
Sec Filings
- 12/15/25 - Form 144
- 12/15/25 - Form 144
- 12/15/25 - Form 144
- RCUS's page on the SEC website